New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Myriad Genetics, Inc. announced new data from the largest meta-analysis of its Prolaris Biopsy Test, demonstrating its strong prognostic performance in localized prostate cancer. The study, involving over 8,000 patients, showed that Prolaris provides significant additional insight beyond conventional clinical risk categories, aiding in personalized risk stratification and treatment decisions. These findings support Prolaris's role in identifying patients suitable for active surveillance versus those requiring treatment or treatment escalation.
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
A large-scale meta-analysis involving over 8,000 patients demonstrated that Myriad Genetics' Prolaris Biopsy Test significantly improves prognostic information beyond conventional clinical risk categories for localized prostate cancer. Published in Clinical Genitourinary Cancer, the study showed Prolaris's effectiveness in risk stratification for distant metastasis and prostate cancer-specific mortality across all NCCN risk groups and management strategies. This evidence supports Prolaris in guiding initial prostate cancer management discussions, aiding shared decision-making, and identifying patients suitable for active surveillance versus those needing treatment or escalation.
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Myriad Genetics, Inc. announced new data from the largest individual-patient-data meta-analysis of its Prolaris Biopsy Test, demonstrating its strong prognostic performance in localized prostate cancer. The study, published in Clinical Genitourinary Cancer, found that Prolaris adds significant prognostic information beyond conventional clinical risk categories, aiding in risk stratification, treatment decisions, and identifying appropriate candidates for active surveillance or treatment escalation. The analysis pooled data from 14 studies involving over 8,000 patients, showing Prolaris's effectiveness across various risk groups and management strategies.
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Myriad Genetics, Inc. announced new data from the largest meta-analysis of its Prolaris Biopsy Test, demonstrating its effectiveness in providing significant prognostic information for localized prostate cancer patients. The study, published in Clinical Genitourinary Cancer, found that Prolaris adds insight beyond conventional clinical risk categories, helping to inform management decisions such as active surveillance versus treatment. This robust evidence from over 8,000 patients reinforces Prolaris's role in personalized risk stratification for metastasis and prostate cancer-specific mortality.
Sera Prognostics adds former Myriad Genetics CEO to board
Sera Prognostics (NASDAQ:SERA) has appointed Mark Capone, former CEO of Myriad Genetics, to its Board of Directors. Capone brings extensive experience in precision medicine and commercializing diagnostic products. The company, which develops the PreTRM test for preterm birth risk, sees his expertise as valuable for expanding test adoption, despite facing recent financial headwinds and a significant revenue decline in Q1 2026.
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com
Sera Prognostics Inc. announced that Mark Capone, former CEO of Myriad Genetics, has joined its Board of Directors. Capone's expertise in commercializing diagnostic products and navigating reimbursement environments is expected to be valuable as Sera Prognostics expands the adoption of its PreTRM test, which predicts preterm birth risk. The company has recently faced financial headwinds, but new legislative developments in Illinois expanding Medicaid coverage for proteomic blood tests like PreTRM could improve its market position.
MYGN - Myriad Genetics Inc Latest SEC Filings
This article provides the latest SEC filings and detailed financial data for Myriad Genetics Inc. (MYGN), including key metrics like market capitalization, income, sales, P/E ratios, and stock performance data. It also lists insider and institutional ownership, profitability margins, and various technical indicators, offering a comprehensive snapshot of the company's financial health and stock activity.
Price to earnings forward of Myriad Genetics, Inc. – NASDAQ:MYGN
This page from TradingView provides financial information for Myriad Genetics, Inc. (NASDAQ: MYGN), specifically focusing on its forward price-to-earnings ratio. While the content displays navigation elements and platform features, it highlights the company's stock symbol and market.
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Myriad (MYGN) shares surged 8.3% after investors reacted positively to the expanded availability of its Precise MRD assay for various cancers. While the company's Q2 earnings are projected to show a loss and revenue decline, the stock currently holds a Zacks Rank #2 (Buy). Investors are advised to monitor earnings estimate revisions for future stock performance.
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Myriad (MYGN) shares surged 8.3% following increased investor optimism due to the expanded availability of its Precise MRD test for various cancers. Despite this recent gain, the stock's future movement is uncertain as the consensus EPS estimate for the quarter has remained unchanged, and stock prices typically don't sustain upward trends without corresponding revisions in earnings estimates. Investors should monitor MYGN, which currently holds a Zacks Rank #2 (Buy), for continued strength.
Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN
This article focuses on the "Price to sales forward" financial metric for Myriad Genetics, Inc. (NASDAQ: MYGN). It presents a financial overview of the company's valuation based on this specific forward-looking sales metric. The content contextually appears to be a stub or a section of a larger financial data presentation on TradingView.
Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN)
This article provides an overview of Myriad Genetics, Inc. (NASDAQ: MYGN) stock performance, financial data, and analyst estimates. It details the current stock price, historical highs and lows, market capitalization, and upcoming earnings report dates. The article also includes analyst forecasts for MYGN's future price and discusses the stock's volatility and technical analysis ratings.
Myriad Genetics, Inc. Actuals & Estimates (HAM:MYD)
This article provides financial actuals and estimates for Myriad Genetics, Inc. (HAM:MYD), including income statement, balance sheet, and cash flow data. It covers analyst forecasts, historical stock prices, upcoming earnings dates, and past earnings and revenue results, noting that Myriad Genetics does not pay dividends.
897518 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Myriad Genetics, Inc. (897518) stock, based on analyst opinions. It details the current stock performance, historical highs and lows, market capitalization, and upcoming earnings reports, without offering investment advice.
MYGN Forecast — Price Target — Prediction for 2027
This article provides a forecast for Myriad Genetics, Inc. (MYGN) stock, including current price, historical performance, analyst price targets, and financial data. It highlights that analysts have a max estimated price target of $10.00 and a min of $4.00, with the stock currently trading at $5.88. The company's next earnings report is expected on July 30, 2026, and it does not pay dividends.
Price to sales forward of Myriad Genetics, Inc. – LS:897518
This article displays the "Price to sales forward" value for Myriad Genetics, Inc. (LS:897518) on TradingView. It indicates that for the current period, there is a value and associated change, and notes that the market is closed with no trades. The article is primarily a data point display from a financial platform.
Price to earnings forward of Myriad Genetics, Inc. – LS:897518
This article provides the "Price to earnings forward" data for Myriad Genetics, Inc. (LS:897518) on TradingView. It shows that the market was closed with no trades at the time of publication. The content also lists various data sources and copyright information.
Enterprise value to revenue forward of Myriad Genetics, Inc. – NASDAQ:MYGN
This article provides financial information for Myriad Genetics, Inc. (NASDAQ: MYGN), specifically focusing on its enterprise value to revenue forward. It appears to be a data point or a financial metric overview from a platform like TradingView, lacking detailed analysis or narrative content.
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today
Shares of Myriad Genetics (MYGN) surged 9.2% today after the company expanded the availability of its Precise MRD test for various cancers and announced positive results from a related clinical study. The test, which helps monitor treatment response and cancer recurrence, is now accessible to over 6 million individuals in the U.S. and demonstrated 100% specificity in predicting complete response to breast cancer treatment. This news indicates the market views these developments as significant for the company, although its stock has been volatile.
Myriad Genetics director Daniel Skovronsky resigns from board
Dr. Daniel Skovronsky has resigned from the board of directors of Myriad Genetics, Inc. (NASDAQ:MYGN) effective immediately. The company stated his resignation was not due to any disagreement with Myriad Genetics' operations or policies. This change occurs as the company faces a challenging period, including a recent EPS loss, lower than anticipated revenues, but anticipates profitability this year.
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Myriad Genetics has expanded the availability of its Precise MRD™ test to patients with breast, colorectal, and renal cancers, a significant step in its precision oncology strategy. The company also announced the publication of the MONITOR-Breast study results, which support the clinical validity of Precise MRD in breast cancer by demonstrating its ultrasensitive ctDNA monitoring capabilities for treatment response and identifying patients at risk for residual disease. This expansion and new evidence underscore the test's role in providing dynamic and quantitative molecular insights throughout the cancer care continuum.
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Myriad Genetics has expanded the availability of its Precise MRD™ test for patients with breast, colorectal, and renal cancers, significantly broadening access to its ultrasensitive molecular diagnostic test. This expansion is supported by a new publication, the MONITOR-Breast study, which highlights the clinical validity of Precise MRD in breast cancer, demonstrating its effectiveness in monitoring treatment response and identifying patients at risk of residual disease. The test, which uses whole-genome sequencing to track up to 1,000 variants, provides crucial insights throughout the cancer care continuum, from neoadjuvant therapy to long-term surveillance.
Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake
A Form 4 filing indicates that Myriad Genetics director Daniel Skovronsky holds 195,507 shares of Common Stock in the company. This filing is classified as a holdings entry, not a new purchase or sale, providing transparency on his existing stake. The filing also clarifies that Skovronsky is no longer serving as a director, effective June 17, 2026, and is thus no longer subject to Section 16 reporting.
MYGN PE Ratio & Valuation, Is MYGN Overvalued
Myriad Genetics Inc (MYGN) is currently considered undervalued, with its current forward PS ratio of 0.46 significantly lower than its five-year average of 40.38. The fair price for MYGN is estimated to be between $14.23 and $30.10, indicating it is undervalued by 67.47% compared to its current price of $4.63 USD. While MYGN's P/S ratio of 0.46 is notably above the industry average, its robust revenue growth of 2.30% suggests this premium might be unsustainable.
Form 8K Myriad Genetics Inc For: 23 June By Investing.com
This article announces that Myriad Genetics Inc. filed a Form 8K on June 23, 2026. The filing is typical for reporting significant unscheduled events that shareholders should know about. The company's stock symbol is MYGN.
Myriad Genetics director Daniel Skovronsky resigns from board
Dr. Daniel M. Skovronsky has resigned from the board of directors of Myriad Genetics, effective immediately. The company stated his resignation was not due to any disagreements but did not provide information on a replacement. This development comes amid recent mixed financial results for Myriad Genetics and new corporate initiatives, including a new CTO and a prostate cancer assessment tool.
Myriad widens cancer test access as breast study bolsters its case
Myriad Genetics has expanded the availability of its Precise MRD™ test to include breast, colorectal, and renal cancers, potentially benefiting over 6 million patients in the U.S. This expansion is supported by new findings from the MONITOR-Breast study, published in Future Oncology, which demonstrated the test's high detection rates and effectiveness in predicting treatment response and identifying patients at risk for residual disease. Precise MRD is an ultrasensitive, whole-genome sequencing-based assay designed to track up to 1,000 variants and monitor disease status throughout cancer treatment and surveillance.
Board member Skovronsky exits Myriad Genetics (NASDAQ: MYGN)
Myriad Genetics, Inc. announced that board member Daniel M. Skovronsky, M.D., Ph.D., resigned from his director position effective June 17, 2026. The company stated that his resignation was not due to any disagreements with Myriad Genetics' operations, policies, or practices. This information was reported in an 8-K filing under Item 5.02 regarding departures of directors.
Form 8K Myriad Genetics Inc For: 23 June By Investing.com
This article reports on the filing of a Form 8K by Myriad Genetics Inc. on June 23. It includes market performance data for various indices, commodities, and individual stocks, noting that Myriad Genetics Inc. (MYGN) saw a 2.89% increase. The piece also provides links to other financial news and market analysis from Investing.com.
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Myriad Genetics announced the expanded availability of its ultrasensitive Precise MRD™ test for breast, colorectal, and renal cancers, significantly increasing access for over 6 million U.S. patients. This expansion is supported by new clinical validity data from the MONITOR-Breast study, published in Future Oncology, which demonstrated the test's effectiveness in monitoring treatment response and identifying patients at higher risk for residual disease in breast cancer. Precise MRD uses whole-genome sequencing to create personalized panels for precise disease monitoring throughout the cancer care continuum.
Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Myriad Genetics Inc (MYGN) stock, focusing on its historical dividend payouts and stock split events. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also presents current stock performance and market capitalization.
Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Myriad Genetics Inc (MYGN) as of April 6, covering analysis by business segment and geographical region. The company's main revenue streams are Hereditary Cancer, Prenatal, Pharmacogenomics, and Tumor Profiling, with Hereditary Cancer being the largest contributor. A significant majority of Myriad Genetics' revenue is generated within the United States.
Myriad Genetics Inc (MYGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Myriad Genetics Inc (MYGN), highlighting its current earnings forecast score of 5.82, ranking it 184 out of 203 in its industry. Analysts have set an average price target of $8.00 for MY
Myriad Genetics Inc (MYGN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Myriad Genetics Inc (MYGN) as of June 16, 2026. The company's valuation score is 8.29, ranking it 98th in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.99, which is noted as being below its recent high and above its recent low.
Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan
Myriad Genetics CEO Samraat S. Raha acquired 3,542 shares of common stock on June 11, 2026, through the company's Amended and Restated 2012 Employee Stock Purchase Plan at $3.936 per share. This transaction increases his direct holdings to 1,068,083 shares and is considered a routine, plan-based acquisition exempt under SEC Rules 16b-3(d) and 16b-3(c).
Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan
Myriad Genetics Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock through the company's Employee Stock Purchase Plan at $3.936 per share. This transaction, exempt under Rule 16b-3(d) and Rule 16b-3(c), increased his direct holdings to 573,363 shares. The acquisition is noted as a routine, compensation-related event rather than an open-market purchase.
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
Myriad Genetics (MYGN) is positioned for growth due to new product launches, particularly in oncology testing, and a sound solvency profile, despite foreign exchange headwinds. The company's focus on germline and tumor testing, alongside FDA approvals and upcoming AI-enhanced tests, is expected to capitalize on market opportunities. However, its stock performance has lagged the industry and S&P 500 over the past year.
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts
Myriad Genetics (NASDAQ:MYGN) has received an average "Hold" rating from six analysts, with a consensus 12-month price target of $6.50. The company recently reported quarterly earnings that missed estimates, with an EPS of -$0.09 and revenue of $200.4 million, despite a 2.3% year-over-year revenue increase. Insider transactions show a director buying shares and another selling under a Rule 10b5-1 plan, while institutional investors hold approximately 99.02% of the stock.
Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan
Myriad Genetics Inc. director Rashmi Kumar sold 15,000 shares of common stock on June 8, 2026, at a weighted average price of $4.4562 per share, totaling $66,843. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Kumar directly owns 171,889 shares of Myriad Genetics Common Stock.
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
Myriad Genetics (MYGN) is positioned for growth due to new product launches, particularly in oncology testing, and sound solvency, despite share price declines and foreign exchange headwinds. The company is actively expanding its diagnostic offerings, including FDA-approved companion diagnostics and AI-enhanced tests. While the stock has underperformed its industry and the S&P 500, analysts see potential for revenue growth in 2026.
[144] MYRIAD GENETICS INC SEC Filing
This SEC filing details a Form 144 Notice of Proposed Sale of Securities for MYRIAD GENETICS INC (MYGN). The filing indicates an intent to sell 15,000 shares of common stock with an aggregate market value of $68,850.00, acquired via restricted stock vesting. The proposed sale date is June 8, 2026, on NASDAQ.
Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis
Myriad Genetics (MYGN) director Mark Steven Davis was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan, bringing his total direct holdings to 106,665 common shares. These RSUs were granted at no purchase price and will vest on the earlier of the first anniversary of the grant date or the next annual stockholders' meeting. This transaction was an equity compensation award, not an open-market purchase or sale.
Myriad Genetics (MYGN) director awarded 59,701 restricted stock units
Myriad Genetics (MYGN) director Lee Nisley Newcomer was granted 59,701 restricted stock units, as reported in a recent Form 4 SEC filing. These units, awarded at no purchase price under the company’s 2026 Equity Incentive Plan, will vest upon the earlier of the first anniversary of the grant date or the next annual stockholders' meeting. Following this grant, Newcomer directly holds a total of 191,842 shares or share-equivalent units in the company.
Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units
Myriad Genetics director Colleen F. Reitan was granted 59,701 restricted stock units (RSUs) under the company's 2026 Employee, Director and Consultant Equity Incentive Plan. This equity award, which is compensation-related rather than a stock purchase, increases her direct holdings to 152,030 shares. The RSUs will vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.
Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro
Myriad Genetics (MYGN) director Paul Bisaro has been granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Employee, Director and Consultant Equity Incentive Plan. These RSUs, which have no purchase price, will vest on the earlier of one year from the grant date or the next annual stockholder meeting. Following this grant, Bisaro directly holds 157,142 shares of common stock, representing a standard equity compensation practice to align director interests with shareholders.
Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant
Myriad Genetics (MYGN) Director Heinrich Dreismann was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan. These RSUs, awarded at no cash cost, will vest upon the earlier of one year from the grant date or the next annual stockholder meeting. Following this grant, Dreismann directly holds 231,145 shares of Myriad Genetics common stock.
Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award
Myriad Genetics (NASDAQ: MYGN) director Rashmi Kumar was granted 59,701 restricted stock units (RSUs) as an equity award, bringing her direct holdings to 186,889 shares. These RSUs were granted at no cash cost under the company's 2026 Employee, Director and Consultant Equity Incentive Plan and will vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting. Each RSU represents a contingent right to receive one share of common stock upon vesting.
[Form 4] MYRIAD GENETICS INC Insider Trading Activity
Myriad Genetics Inc. director S. Louise Phanstiel was granted 59,701 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan at no cash cost. These RSUs will vest upon the earlier of one year from the grant date or the next annual stockholders' meeting. Following this transaction, Phanstiel directly holds 341,652 shares of common stock.
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
Myriad Genetics (MYGN) shares have risen 7.1% since its last earnings report, outperforming the S&P 500. Despite missing Q1 earnings estimates with an adjusted loss of 9 cents per share and a revenue miss, the company's Cancer Care Continuum and Mental Health businesses showed growth. Myriad maintains its full-year 2026 revenue and gross margin guidance, with a Zacks Rank #2 (Buy) indicating an expectation of above-average returns.
Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans
Myriad Genetics (NASDAQ: MYGN) held its 2026 Annual Meeting of Stockholders, where shareholders approved significant expansions to the company's equity and stock purchase plans. This included an amendment to the 2012 Employee Stock Purchase Plan adding 4,000,000 shares and the adoption of the 2026 Employee, Director and Consultant Equity Incentive Plan with an initial reserve of 8,463,567 shares. Shareholders also elected three Class III directors, ratified Ernst & Young LLP as the independent auditor for 2026, and approved named executive officer compensation on an advisory basis.
